Nothing Special   »   [go: up one dir, main page]

TW200716120A - Pyrazolo-pyrimidine derivatives as mGluR2 antagonists - Google Patents

Pyrazolo-pyrimidine derivatives as mGluR2 antagonists

Info

Publication number
TW200716120A
TW200716120A TW095104260A TW95104260A TW200716120A TW 200716120 A TW200716120 A TW 200716120A TW 095104260 A TW095104260 A TW 095104260A TW 95104260 A TW95104260 A TW 95104260A TW 200716120 A TW200716120 A TW 200716120A
Authority
TW
Taiwan
Prior art keywords
pyrimidine derivatives
pyrazolo
mglur2 antagonists
treating
derivatives
Prior art date
Application number
TW095104260A
Other languages
English (en)
Inventor
Silvia Gatti Mcarthur
Erwin Goetschi
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TW200716120A publication Critical patent/TW200716120A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW095104260A 2005-02-11 2006-02-08 Pyrazolo-pyrimidine derivatives as mGluR2 antagonists TW200716120A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101027 2005-02-11

Publications (1)

Publication Number Publication Date
TW200716120A true TW200716120A (en) 2007-05-01

Family

ID=36090752

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095104260A TW200716120A (en) 2005-02-11 2006-02-08 Pyrazolo-pyrimidine derivatives as mGluR2 antagonists

Country Status (18)

Country Link
US (1) US7361659B2 (zh)
EP (1) EP1851225B1 (zh)
JP (1) JP4708438B2 (zh)
KR (1) KR100968291B1 (zh)
CN (1) CN101115755B (zh)
AR (1) AR052568A1 (zh)
AT (1) ATE512966T1 (zh)
AU (1) AU2006212457B2 (zh)
BR (1) BRPI0607927A2 (zh)
CA (1) CA2597608C (zh)
ES (1) ES2365406T3 (zh)
IL (1) IL184712A (zh)
MX (1) MX2007009106A (zh)
NO (1) NO20073876L (zh)
RU (1) RU2402553C2 (zh)
TW (1) TW200716120A (zh)
WO (1) WO2006084634A1 (zh)
ZA (1) ZA200706353B (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085398A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009110901A1 (en) * 2008-03-06 2009-09-11 Sanofi-Aventis Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur
US8207181B2 (en) 2008-03-06 2012-06-26 Sanofi Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof
EP2604602A4 (en) 2010-08-11 2013-12-18 Taisho Pharmaceutical Co Ltd HETEROARYLPYRAZOLDERIVAT
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
JP6073343B2 (ja) * 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
MX2015004604A (es) 2012-10-23 2015-10-08 Hoffmann La Roche Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas.
RU2016144702A (ru) 2014-04-23 2018-05-24 Ф. Хоффманн-Ля Рош Аг Антагонисты mglu2/3 для лечения интеллектуальной недостаточности
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
WO2016073889A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
HUE066864T2 (hu) 2014-11-06 2024-09-28 Bial R&D Invest S A Helyettesített pirazolo(1,5-a)pirimidinek és alkalmazásuk orvosi rendellenességek kezelésében
AU2015342883B2 (en) 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
WO2016087489A1 (en) 2014-12-03 2016-06-09 Janssen Pharmaceutica Nv Radiolabelled mglur2 pet ligands
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
LT3389727T (lt) 2015-12-18 2020-10-12 Janssen Pharmaceutica Nv Radioaktyviai pažymėti mglur2/3 pet ligandai
US11045562B2 (en) 2015-12-18 2021-06-29 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
EP3440083A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
CA3020310A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
BR112018070586A8 (pt) 2016-04-06 2023-03-14 Lysosomal Therapeutics Inc Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos
MX2018013529A (es) 2016-05-05 2019-07-04 Lysosomal Therapeutics Inc Imidazo[1,2-b]piridazinas sustituidas, imidazo[1,5-b]piridazinas sustituidas, compuestos relacionados y su uso en el tratamiento de trastornos médicos.
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US10647710B2 (en) * 2017-01-09 2020-05-12 Medshine Discovery Inc. Thiazole derivative and applications thereof
JP7242548B2 (ja) 2017-11-24 2023-03-20 住友ファーマ株式会社 ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体及びその医薬用途
KR102535452B1 (ko) * 2018-07-06 2023-05-26 파에노 테라퓨틱스 씨오., 엘티디. 티아졸 화합물의 결정형 및 이의 응용

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029109A1 (en) 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as crf receptor antagonists
PT891978E (pt) 1997-07-18 2002-07-31 Hoffmann La Roche Derivados de 5h-tiazolo (3,2-a) pirimidina
AU4203500A (en) * 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
MXPA03009311A (es) * 2001-04-12 2004-02-12 Hoffmann La Roche Derivados de dihidro-benzo[b][1,4]diazepin-2-ona como antagonistas ii del receptor metabotropico de glutamato (mglur2).
EP1615904B1 (en) * 2003-04-15 2008-02-27 AstraZeneca AB Substituted benzosulphonamides as potentiators of glutamate receptors
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
RU2378277C2 (ru) * 2004-06-21 2010-01-10 Ф. Хоффманн-Ля Рош Аг Производные пиразолпиримидина

Also Published As

Publication number Publication date
ES2365406T3 (es) 2011-10-04
AU2006212457B2 (en) 2011-04-14
AR052568A1 (es) 2007-03-21
CA2597608A1 (en) 2006-08-17
US7361659B2 (en) 2008-04-22
CA2597608C (en) 2013-12-24
MX2007009106A (es) 2007-09-11
CN101115755A (zh) 2008-01-30
CN101115755B (zh) 2013-01-16
EP1851225B1 (en) 2011-06-15
JP2008530042A (ja) 2008-08-07
AU2006212457A1 (en) 2006-08-17
BRPI0607927A2 (pt) 2009-10-20
JP4708438B2 (ja) 2011-06-22
ATE512966T1 (de) 2011-07-15
RU2007128624A (ru) 2009-03-20
KR100968291B1 (ko) 2010-07-07
NO20073876L (no) 2007-09-10
KR20070104592A (ko) 2007-10-26
EP1851225A1 (en) 2007-11-07
IL184712A (en) 2013-05-30
IL184712A0 (en) 2007-12-03
WO2006084634A1 (en) 2006-08-17
ZA200706353B (en) 2009-09-30
US20060183756A1 (en) 2006-08-17
RU2402553C2 (ru) 2010-10-27

Similar Documents

Publication Publication Date Title
TW200716120A (en) Pyrazolo-pyrimidine derivatives as mGluR2 antagonists
TW200716121A (en) Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists
TW200740789A (en) Pyridine and pyrimidine derivatives as mGluR2 antagonists
MX2009010505A (es) Derivados de piridina y pirimidina como antagonistas de mglur2.
TW200700391A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
IL189987A0 (en) Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
MX2009006540A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides.
WO2007115077A3 (en) Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2008032191A3 (en) Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
MX2009006921A (es) Derivados azaespiro.
GB0625648D0 (en) Compounds
TW200806300A (en) New therapeutic combinations for the treatment of depression
TNSN07360A1 (en) Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
TW200800946A (en) Substituted piperazines as metabotropic glutamate receptor antagonists
MX2007005189A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarinico m3.
TW200720260A (en) Prokineticin 1 receptor antagonists
TW200716566A (en) Prokineticin 2 receptor antagonists
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
CY1113146T1 (el) 11-φωσφο-στεροειδη παραγωγα ως τροποποιητες του υποδοχεα προγεστερονης